RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
-5.97%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$522M
AUM Growth
+$522M
(-17%)
Cap. Flow
-$70.4M
Cap. Flow
% of AUM
-13.5%
Top 10 Holdings %
Top 10 Hldgs %
27.83%
Holding
119
New
12
Increased
37
Reduced
37
Closed
11
Top Buys
| 1 |
Gilead Sciences
GILD
|
$18.6M |
| 2 |
Medtronic
MDT
|
$15.3M |
| 3 |
Pfizer
PFE
|
$10.8M |
| 4 |
Elevance Health
ELV
|
$8.38M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$5.42M |
Top Sells
| 1 |
SHPG
Shire pic
SHPG
|
$26.6M |
| 2 |
CELG
Celgene Corp
CELG
|
$10.8M |
| 3 |
UnitedHealth
UNH
|
$8.8M |
| 4 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$8.56M |
| 5 |
Merck
MRK
|
$7.65M |
Sector Composition
| 1 | Healthcare | 94.79% |
| 2 | Financials | 1.61% |
| 3 | Technology | 0.16% |
| 4 | Energy | 0.11% |
| 5 | Consumer Discretionary | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Dynavax Technologies
DVAX
$1.19B
| $1.92M | 0.37% |
485,000
+185,000
| +62% | +$731K |
|
|
CMRX
77
DELISTED
Chimerix, Inc.
CMRX
| $1.84M | 0.35% |
400,000
-150,000
| -27% | -$690K |
|
78
Halozyme
HALO
$8.75B
| $1.78M | 0.34% |
180,000
-70,000
| -28% | -$691K |
|
79
Neurocrine Biosciences
NBIX
$13.5B
| $1.55M | 0.3% |
40,000
| – | – |
|
|
AERI
80
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $1.33M | 0.25% |
+35,000
| New | +$1.33M |
|
81
Insulet
PODD
$24.2B
| $1.32M | 0.25% |
35,000
-22,000
| -39% | -$829K |
|
|
TTPH
82
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $1.21M | 0.23% |
300,000
| – | – |
|
|
RGLS
83
DELISTED
Regulus Therapeutics
RGLS
| $1.05M | 0.2% |
468,175
+168,175
| +56% | +$378K |
|
84
Becton Dickinson
BDX
$54.3B
| $828K | 0.16% |
+5,000
| New | +$828K |
|
|
ACHN
85
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $686K | 0.13% |
166,000
-100,000
| -38% | -$413K |
|
86
Pediatrix Medical
MD
$1.45B
| $600K | 0.12% |
9,000
| – | – |
|
87
Tandem Diabetes Care
TNDM
$834M
| $503K | 0.1% |
234,000
| – | – |
|
88
Adverum Biotechnologies
ADVM
$68.2M
| $447K | 0.09% |
154,006
| – | – |
|
89
Viatris
VTRS
$12.3B
| $382K | 0.07% |
+10,000
| New | +$382K |
|
90
Astria Therapeutics
ATXS
$394M
| $361K | 0.07% |
100,000
| – | – |
|
91
JPMorgan Chase
JPM
$824B
| $353K | 0.07% |
4,087
+1,399
| +52% | +$121K |
|
92
Wells Fargo
WFC
$258B
| $337K | 0.06% |
6,118
+1,596
| +35% | +$87.9K |
|
93
Ocular Therapeutix
OCUL
$2.25B
| $335K | 0.06% |
40,000
| – | – |
|
94
STAAR Surgical
STAA
$1.35B
| $312K | 0.06% |
+28,711
| New | +$312K |
|
|
CNCE
95
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $310K | 0.06% |
30,099
| – | – |
|
96
Microsoft
MSFT
$3.76T
| $298K | 0.06% |
4,793
+1,653
| +53% | +$103K |
|
97
IBM
IBM
$227B
| $293K | 0.06% |
1,766
+623
| +55% | +$103K |
|
98
Exxon Mobil
XOM
$477B
| $288K | 0.06% |
3,195
+1,093
| +52% | +$98.5K |
|
99
Ford
F
$46.2B
| $273K | 0.05% |
22,511
+7,900
| +54% | +$95.8K |
|
100
Qualcomm
QCOM
$170B
| $269K | 0.05% |
4,126
+1,257
| +44% | +$82K |
|